Marvel Biosciences Corp.
MRVL.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -341.70K | -203.80K | -432.10K | -226.50K | -172.40K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.20K | 15.70K | 193.10K | 3.30K | 5.20K |
| Change in Net Operating Assets | 309.90K | -4.20K | -9.80K | -42.10K | -10.00K |
| Cash from Operations | -18.60K | -192.20K | -248.70K | -265.30K | -177.30K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 500.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.60K | -- | 500.00K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -31.40K | -- | -- |
| Cash from Financing | 1.80K | -- | 342.20K | 0.00 | 370.30K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.70K | -192.20K | 93.50K | -265.30K | 193.10K |